BTTX (Better Therapeutics) Common Stock: $0.00 Mil (As of Sep. 2023)


What is Better Therapeutics Common Stock?

Better Therapeutics BTTX Common Stock is $0.00 Mil as of Sep. 2023.

Better Therapeutics's quarterly common stock increased from Mar. 2023 ($0.00 Mil) to Jun. 2023 ($0.00 Mil) and increased from Jun. 2023 ($0.00 Mil) to Sep. 2023 ($0.00 Mil).

Better Therapeutics's annual common stock increased from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($0.00 Mil) but then stayed the same from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil).

Better Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Better Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Better Therapeutics Common Stock Chart

Better Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Common Stock
0.21 0.00 0.00 0.00

Better Therapeutics Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Better Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.00 Mil mean?
Better Therapeutics (BTTX) has a Common Stock of $0.00 Mil as of Sep. 2023. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Better Therapeutics and its competitors.
Is Better Therapeutics' Common Stock too high?
Better Therapeutics' current Common Stock is $0.00 Mil.
How does Better Therapeutics' Common Stock compare to CYCN and CELZ?
Better Therapeutics' Common Stock of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Better Therapeutics and its competitors. Better Therapeutics's current Common Stock is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Better Therapeutics stock overvalued right now?
Better Therapeutics (BTTX) has a current Common Stock of $0.00 Mil. The current Common Stock is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Better Therapeutics (BTTX), the current Common Stock is $0.00 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Better Therapeutics Business Description

Address 548 Market Street, Suite 49404, San Francisco, CA, USA, 94104
Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions.